Lifecore director granted 25,907 RSUs

Director Humberto Calheiros Antunes of Lifecore Biomedical, Inc. reported receiving an award of 25,907 shares of common stock in the form of restricted stock units.

Rhea-AI Filing Summary

Director Humberto Calheiros Antunes of Lifecore Biomedical, Inc. reported receiving an award of 25,907 shares of common stock in the form of restricted stock units. The award has no cash exercise price and increases his direct holdings to 72,967 shares after the transaction.

The restricted stock units convert into common stock on a 1-for-1 basis and will vest on the earlier of June 4, 2027 or the date of Lifecore’s 2027 annual stockholders’ meeting, provided that meeting occurs at least 50 weeks after June 4, 2026.

Insider Trade Summary

Grant/Award: 25,907 shares

Grant/Award 1 txn

Insider Antunes Humberto Calheiros

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,907	$0.00	$0.00

Holdings After Transaction: Common Stock — 72,967 shares (Direct)

Footnotes (2)

1. F1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
2. F2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Key Figures

RSU grant size: 25,907 shares Grant price per share: $0.0000 per share Total shares after transaction: 72,967 shares +3 more

6 metrics

RSU grant size 25,907 shares Restricted stock units of common stock granted to director

Grant price per share $0.0000 per share Reported transaction price for RSU award

Total shares after transaction 72,967 shares Director’s direct holdings following the grant

Conversion ratio 1-for-1 Each restricted stock unit converts into one common share

Vesting date reference June 4, 2027 Latest vesting date; earlier vesting at 2027 annual meeting possible

Vesting condition window 50 weeks Annual meeting must be at least 50 weeks after June 4, 2026

Key Terms

restricted stock units, 1 for 1 basis, vests, annual meeting of stockholders, +1 more

5 terms

restricted stock units financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

1 for 1 basis financial

"The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis."

vests financial

"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027"

annual meeting of stockholders financial

"Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lifecore Biomedical (LFCR) report for Humberto Calheiros Antunes?

Lifecore Biomedical reported that director Humberto Calheiros Antunes received a grant of 25,907 restricted stock units of common stock. These units were awarded at no cash cost and increase his direct ownership position, reflecting a compensation-related equity grant rather than an open-market share purchase.

How many Lifecore Biomedical (LFCR) shares does Humberto Calheiros Antunes hold after this Form 4?

After the reported grant, Humberto Calheiros Antunes directly holds 72,967 shares of Lifecore Biomedical common stock. This figure includes the newly granted restricted stock units that convert into common shares on a 1-for-1 basis, as disclosed in the Form 4 filing details.

What is the size of the restricted stock unit grant reported by Lifecore Biomedical (LFCR)?

The Form 4 shows a grant of 25,907 restricted stock units of Lifecore Biomedical common stock. These units were issued with a price of $0.0000 per share, indicating a compensation award rather than a market transaction or purchase by the reporting director.

When do the newly granted Lifecore Biomedical (LFCR) restricted stock units vest?

The restricted stock units vest on the earlier of June 4, 2027 or the date of Lifecore Biomedical’s 2027 annual stockholders’ meeting. The annual meeting date must be at least 50 weeks after June 4, 2026, according to the vesting schedule described in the filing footnotes.

How do the Lifecore Biomedical (LFCR) restricted stock units convert into common stock?

The filing states that the restricted stock units convert into Lifecore Biomedical common stock on a 1-for-1 basis. This means each unit becomes one share of common stock when vested, providing straightforward equity exposure aligned with the company’s existing common shares outstanding.

Was the Lifecore Biomedical (LFCR) director’s Form 4 transaction a market purchase or a compensation grant?

The transaction was a compensation-related grant, not a market purchase. The Form 4 labels the code as an “A” transaction for a grant or award, with 25,907 shares at a price of $0.0000 per share, indicating no open-market buying or selling activity occurred.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Antunes Humberto Calheiros

(Last) (First) (Middle)

C/O LIFECORE BIOMEDICAL, INC.

3515 LYMAN BLVD.

(Street)

CHASKA MINNESOTA 55318

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		25,907	A	(1)(2)	72,967	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

2. Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Remarks:

	/s/ Courtney Schuler, Attorney-In-Fact for Humberto C Antunes	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)